Skip to main content

ADVERTISEMENT

Larry Blandford, PharmD2—Column Editor

Equivalars: Could They Bring Down the Cost of Rx Drugs?
Pharma Insights
04/21/2020
Sejal Jonas, PharmD1
Larry Blandford, PharmD2—Column Editor
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution trying...
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution trying...
A...
04/21/2020
Journal of Clinical Pathways